Dyax (NASDAQ: [[ticker:DYAX]]), a Cambridge, MA-based developer of a drug for an inflammatory disease, has raised $59.6 million in a stock deal. Last month the company raised $51.8 million through the sale of 17 million shares at $3.25 per share, and raised an additional $8 million when underwriter Jefferies & Company exercised its over-allotment option to purchase an additional 2.55 million shares of common stock at $3.25 per share, in a sale that closed today. The funding from the stock offering will go to Dyax’s Kalbitor (ecallantide), a drug for treating acute attacks of an inflammatory disease called hereditary angioedema.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
